Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 390

1.

Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.

Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR.

Blood. 2011 Feb 10;117(6):e67-74. doi: 10.1182/blood-2010-08-299016. Epub 2010 Dec 10.

2.

Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.

Stufano F, Baronciani L, Pagliari MT, Franchi F, Cozzi G, Garcia-Oya I, Bucciarelli P, Boscarino M, Peyvandi F.

J Thromb Haemost. 2015 Oct;13(10):1806-14. doi: 10.1111/jth.13062. Epub 2015 Aug 27.

PMID:
26206100
3.

Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.

Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH.

Haemophilia. 2013 Jul;19(4):590-4. doi: 10.1111/hae.12117. Epub 2013 Mar 18.

4.

Plasma glycocalicin as a source of GPIbalpha in the von Willebrand factor ristocetin cofactor ELISA.

Vanhoorelbeke K, Pareyn I, Schlammadinger A, Vauterin S, Hoylaerts MF, Arnout J, Deckmyn H.

Thromb Haemost. 2005 Jan;93(1):165-71.

PMID:
15630508
5.

Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay.

Riddell AF, Jenkins PV, Nitu-Whalley IC, McCraw AH, Lee CA, Brown SA.

Br J Haematol. 2002 Jan;116(1):187-92.

PMID:
11841416
6.

A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels.

Federici AB, Canciani MT, Forza I, Mannucci PM, Marchese P, Ware J, Ruggeri ZM.

Haematologica. 2004 Jan;89(1):77-85.

7.

Development of an ELISA method for testing VWF ristocetin cofactor activity with improved sensitivity and reliability in the diagnosis of von Willebrand disease.

Zhao Y, Gu Y, Ji S, Yang J, Yu Z, Ruan C.

Eur J Haematol. 2012 May;88(5):439-45. doi: 10.1111/j.1600-0609.2012.01760.x. Epub 2012 Feb 15.

PMID:
22268616
8.

Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?

Casonato A, Pontara E, Bertomoro A, Sartorello F, Cattini MG, Girolami A.

Br J Haematol. 2001 Mar;112(3):578-83.

PMID:
11260057
9.

Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges.

Hayward CP, Moffat KA, Graf L.

Int J Lab Hematol. 2014 Jun;36(3):334-40. doi: 10.1111/ijlh.12220. Review.

PMID:
24750680
10.

Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies.

Costa-Pinto J, Pérez-Rodríguez A, del C Goméz-del-Castillo M, Lourés E, Rodríguez-Trillo A, Batlle J, López-Fernández MF.

Haemophilia. 2014 Jul;20(4):559-67.

PMID:
25077350
11.

Laboratory diagnosis and molecular classification of von Willebrand disease.

Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.

Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Review.

PMID:
19506352
12.

A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.

Casonato A, Sartorello F, Pontara E, Gallinaro L, Bertomoro A, Grazia Cattini M, Daidone V, Szukowska M, Pagnan A.

Thromb Haemost. 2007 Dec;98(6):1182-7.

PMID:
18064311
13.

Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.

Geisen U, Zieger B, Nakamura L, Weis A, Heinz J, Michiels JJ, Heilmann C.

Thromb Res. 2014 Aug;134(2):246-50. doi: 10.1016/j.thromres.2014.04.033. Epub 2014 May 17.

PMID:
24891215
14.

Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin.

Patzke J, Budde U, Huber A, Méndez A, Muth H, Obser T, Peerschke E, Wilkens M, Schneppenheim R.

Blood Coagul Fibrinolysis. 2014 Dec;25(8):860-70. doi: 10.1097/MBC.0000000000000169.

PMID:
25192242
16.

Molecular genetics of type 2 von Willebrand disease.

Fressinaud E, Mazurier C, Meyer D.

Int J Hematol. 2002 Jan;75(1):9-18. Review.

PMID:
11843298
17.

A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.

Vanhoorelbeke K, Cauwenberghs N, Vandecasteele G, Vauterin S, Deckmyn H.

Semin Thromb Hemost. 2002 Apr;28(2):161-6.

PMID:
11992239
18.

Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.

Hillery CA, Mancuso DJ, Evan Sadler J, Ponder JW, Jozwiak MA, Christopherson PA, Cox Gill J, Paul Scott J, Montgomery RR.

Blood. 1998 Mar 1;91(5):1572-81.

19.

A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.

Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F.

Haemophilia. 2014 Jan;20(1):147-53. doi: 10.1111/hae.12264. Epub 2013 Sep 12.

PMID:
24028703
20.

A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.

Stepanian A, Ribba AS, Lavergne JM, Fressinaud E, Juhan-Vague I, Mazurier C, Girma JP, Meyer D.

Br J Haematol. 2003 Feb;120(4):643-51.

PMID:
12588351

Supplemental Content

Support Center